Loading...
XMAD
PHM
Market cap1.43bUSD
Apr 09, Last price  
72.50EUR
1D
3.86%
1Q
-3.46%
Jan 2017
131.55%
IPO
56.09%
Name

Pharma Mar SA

Chart & Performance

D1W1MN
P/E
48.02
P/S
7.17
EPS
1.51
Div Yield, %
0.86%
Shrs. gr., 5y
-0.88%
Rev. gr., 5y
15.30%
Revenues
175m
+10.56%
471,00076,240,00085,459,000105,260,000123,387,000153,508,000152,486,000138,229,000140,476,000148,686,000192,814,000180,943,000179,337,000162,163,00085,819,000269,961,000229,831,000196,343,000158,153,000174,855,000
Net income
26m
+2,197.71%
42,000-48,648,000-50,665,000-43,737,000-28,136,000-12,332,000-1,373,0006,593,00011,322,00013,115,0006,588,000-24,082,000-26,745,000-5,535,000-9,180,000137,262,00092,859,00049,356,0001,137,00026,125,000
CFO
6m
P
-33,034,000-56,114,000-49,158,000-35,656,000-22,666,000-21,899,000-4,282,0006,319,00016,345,00022,109,00011,101,000-8,414,000-1,459,000-16,340,000-26,137,000278,942,00025,677,00038,321,000-13,446,0006,027,000
Dividend
Jun 12, 20240.65 EUR/sh
Earnings
Apr 21, 2025

Profile

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
URL
https://www.pharmamar.com/es/
IPO date
Nov 02, 2015
Employees
515
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
174,855
10.56%
158,153
-19.45%
196,343
-14.57%
Cost of revenue
109,006
150,720
140,329
Unusual Expense (Income)
NOPBT
65,849
7,433
56,014
NOPBT Margin
37.66%
4.70%
28.53%
Operating Taxes
(14,140)
(4,760)
(5,566)
Tax Rate
NOPAT
79,989
12,193
61,580
Net income
26,125
2,197.71%
1,137
-97.70%
49,356
-46.85%
Dividends
(11,420)
(11,689)
(11,761)
Dividend yield
0.81%
1.59%
1.01%
Proceeds from repurchase of equity
215
(19,295)
7,049
BB yield
-0.02%
2.62%
-0.61%
Debt
Debt current
9,847
14,805
14,733
Long-term debt
44,472
32,672
31,519
Deferred revenue
17,169
22,137
44,899
Other long-term liabilities
194
896
(284)
Net debt
(11,379)
(121,147)
(152,959)
Cash flow
Cash from operating activities
6,027
(13,446)
38,321
CAPEX
(15,015)
(15,956)
(8,852)
Cash from investing activities
1,033
(43,048)
10,878
Cash from financing activities
(5,350)
(32,137)
(13,370)
FCF
52,266
520
68,330
Balance
Cash
154,527
162,562
182,420
Long term investments
(88,829)
6,062
16,791
Excess cash
56,955
160,716
189,394
Stockholders' equity
179,312
153,251
167,544
Invested Capital
219,842
105,483
142,658
ROIC
49.17%
9.83%
37.82%
ROCE
23.79%
2.87%
18.03%
EV
Common stock shares outstanding
17,640
17,916
18,063
Price
79.80
94.26%
41.08
-36.11%
64.30
12.77%
Market cap
1,407,665
91.26%
735,989
-36.63%
1,161,451
12.63%
EV
1,396,286
614,842
1,008,492
EBITDA
72,622
13,189
61,914
EV/EBITDA
19.23
46.62
16.29
Interest
2,469
2,416
2,376
Interest/NOPBT
3.75%
32.50%
4.24%